LFWD News & Events

Lifeward announced the appointment of Keith Rose as chief medical officer. Rose, who previously served as VP, medical affairs and medical director, Neurosciences at Lifeward, will lead the company's global medical strategy.

Lifeward files to sell 7.26M ordinary shares for holders

Lifeward (LFWD) announced that it has closed on the company's previously announced strategic partnership agreement with Oramed Pharmaceuticals (ORMP). The transaction has positioned Lifeward as a diversified biomedical innovation company with an expected clear path to profitability. Lifeward acquired Oramed's clinical-stage Protein Oral Delivery technology, adding exposure to a large, long-term biotech market opportunity. Through the new partnership, Lifeward has access to up to $47M of capital from Oramed and certain investors, and on March 25, Lifeward accessed $10M of such capital.